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An affective disorder can have a major impact on the life of patients and their 
environment. Not surprisingly, the underlying neurobiology has been the topic of a 
large number of research projects. However, in spite of the efforts made in the 
past decades, the mechanisms and factors that play a role in developing affective 
disorders are far from clear. Moreover, pharmacological treatment of affective 
disorders is still far from ideal. There is thus a need for better understanding and 
improved treatment of these disorders. 
Affective disorders can roughly be divided in mood and anxiety disorders. 
According to the diagnostic and statistical manual (DSM-IV-TR) of the American 
psychiatric association, mood disorders have a disturbance in mood (either 
depressed or the loss of interest or pleasure in nearly all activities) as the 
predominant feature. They are subdivided into depressive disorders, bipolar 
disorders and mood disorders connected with a general medical condition or 
substance induced. Anxiety disorders are as heterogeneous a group as mood 
disorders, with (increased) anxiety as the predominant feature. Examples are 
generalized anxiety disorder (GAD), panic disorder (PD), obsessive-compulsive 
disorder (OCD), phobias and stress disorders. 
The prevalence of affective disorders is higher in females than in males, suggesting 
that estrogen could have an influence on the susceptibility of developing affective 
disorder, however the notion that women are more inclined to seek professional 
help is likely to play a role too. In general three types of treatment are available: 
Antidepressants are considered to be the first choice treatment with the majority of 
mood and anxiety disorders. Benzodiazepines are also used for treating certain 
dimensions of anxiety, but sedation and withdrawal problems have diminished 
their popularity. In addition several types of psychotherapy are available for the 
treatment of affective disorders. 
Clinical depression affects about 16% of the population on at least one occasion in 
their lives (Bland, 1997). This is an average number, however, and much higher 
prevalence rates have been reported in females, but also in some western 
countries. In Australia for instance, one in four women and one in six men will 
suffer from depression. The mean age of onset, from a number of studies, is in the 
late 20s. About twice as many females as males report or receive treatment for 
clinical depression. Though this imbalance is decreasing over the course of recent 
history; this difference seems to completely disappear after the age of 50 - 55, 
when most females have passed the end of menopause. Clinical depression is 
currently the leading cause of disability in the US as well as in other countries, and 
it is expected to become the second leading cause of disability worldwide (after 
heart disease) by the year 2020, according to the World Health Organization 
(Murray & Lopez, 1997). This prognosis is even more alarming considering the 
outcome of a meta-analysis of clinical studies performed with the 6 most 
prescribed antidepressants in the USA versus placebo, suggesting that 
antidepressant treatment was only marginally better than placebo (1-3 points 
improvement on the Hamilton Depression scale) (Khan et al., 2002) 
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Introduction 
Over the past 50 years several antidepressant therapies have been developed to 
treat clinical depression. The first effective antidepressants were based on 
serendipitous findings with the tuberculosis drug iproniazide and belonged to the 
group of monoamine oxidase inhibitors (MAOi’s). These compounds inhibit the 
enzyme responsible for the oxidative degradation of monoamines, resulting in 
increased extracellular levels of monoaminergic neurotransmitters. Occasionally 
MAOi treatment could lead to hypertensive crisis especially with people of 
advanced age. Next, the tricyclic antidepressants (TCAs) were discovered. These 
compounds inhibit the transporters responsible for the reuptake of monoamines, 
also leading to increased extracellular levels of monoamines. However, due to their 
‘dirty’ pharmacological profile, treatment was accompanied with a considerable 
number of side effects. Cleaning up their pharmacological profile has led to 
compounds with a more benign side effect profile, such as the selective serotonin 
re-uptake inhibitors (SSRIs) and the atypical antidepressant mirtazapine. In 
contrast to certain benzodiazepines, all monoamine-based antidepressants have in 
common that their onset of action is around 3 to 6 weeks after the start of the 
treatment, whereas some side effects may occur immediately. Since a number of 
patients do not tolerate these side effects, they may be inclined to abandon 
pharmacotherapy prematurely. Furthermore, clinical studies indicate that 30-40 % 
of the patients do not experience any improvement of their depression after 
treatment, and in reality this percentage may be even higher. Unfortunately, for 
this group of patients no alternative treatments exists (Moncrieff, 2008). 
One could argue that more effective antidepressants can be developed as soon as 
the mechanisms underlying depression are unraveled. However, despite the 
progress of neurobiology in the last 50 years, our knowledge of the pathological 
processes in affective disorders remains poor. The brain is a very complex organ 
protected by the blood-brain-barrier (BBB) and direct neurobiological assessment is 
difficult because invasive techniques are normally not allowed in humans. 
Measurement of neurotransmitters and their metabolites in cerebrospinal fluid 
(CSF), serotonin uptake and receptor binding of blood cells and neuro-endocrine 
strategies have been used as an alternative. However, these approaches must be 
considered as relatively crude and indirect ways to obtain information from the 
normal and pathological brain. Yet, based on clinical and preclinical research, 
several hypotheses of depression have been developed. 
1.1   Hypotheses of affective disorders 
1.1.1   The monoamine hypothesis 
The monoamine hypothesis simply states that depression is caused by a deficiency 
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activity (Schildkraut, 1965). The hypothesis is supported by the following 
observations: 
• The majority of antidepressants increase the extracellular 
levels of monoamines in the brain, either via inhibition of 
monoaminergic metabolism (DELAY et al., 1952) or through 
blockade of monoamine reuptake into the nerve terminal 
(Wolf et al., 1985)  
• Reserpine, an antihypertensive drug, which induces a 
depletion of monoamine stores, is capable of inducing 
symptoms of depression (Goodwin & Bunney, Jr., 1971).  
• Patients successfully treated with SSRI’s fall into remission on 
a low tryptophan (an essential amino acid and precursor of 
serotonin) diet (Spillmann et al., 2001). 
 
The monoamine hypothesis was very attractive because of its simplicity, yet it 
appeared unable to offer an explanation for a number of clinical observations. 
First, the large number of side effects of MAOi’s and TCAs has prompted 
pharmaceutical companies to develop more specific monoamines reuptake 
inhibitors. Combinations of inhibitors for serotonin, noradrenaline and dopamine 
reuptake were also developed. However, focusing on increased monoamine levels 
has not led to considerable improvement of clinical efficacy. Second, the 
monoamine hypothesis fails to explain why a number of drugs that also increase 
brain monoaminergic activity, such as cocaine, amphetamine and fenfluramine are 
devoid of antidepressant efficacy. Third, a relatively large group of patients does 
not respond to monoamine-related antidepressant treatment. Finally, most 
antidepressants increase monoamine levels within hours after administration, but 
the therapeutic response is delayed for several weeks (Baldessarini, 1989). 
The latter has led to adaptations of the monoamine hypothesis stating that 
sustained increased levels of monoamines are necessary to induce desensitization 
of auto- and heteroreceptors, eventually leading to the antidepressant effect (Blier 
et al., 1987). These auto- and heteroreceptors regulate monoaminergic activity 
and it has therefore been proposed that the process of desensitization coincides 
within the time course of the therapeutic antidepressant response. Conversely, 
resensitization of such receptors might offer an explanation for the relapse of 
depressive symptoms after discontinuation of antidepressant treatment. Changes 
in sensitivity of receptors for all three monoamines have been subject to research, 
however most attention has been paid to the 5-HT1A serotonin autoreceptor. As 
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the monoamine receptors have been extensively described elsewhere, only a 
number of important monoamine receptors will shortly be discussed here. 
The ß-adrenoreceptor (ß-AR) may have been the first monoamine receptor which 
has been functionally investigated in relation to chronic antidepressant treatment 
(Banerjee et al., 1977). It appeared that a variety of antidepressant treatments, 
including TCAs, MAOIs and repeated electroconvulsive shock therapy down-
regulated ß-AR density in limbic brain regions, including cerebral cortex and 
hippocampus (Vetulani & Sulser, 1975; Sugrue, 1983). Moreover, nearly all 
antidepressants diminished the ability of ß-ARs to stimulate adenylate cyclase-
mediated cAMP production in these regions (Vetulani & Sulser, 1975; Charney et 
al., 1981). The time needed to establish the changes in receptor density and 
functionality was consistent with the time course of the therapeutic antidepressant 
response.  
The α2-adrenoreceptor subtype has also been studied in relation to major 
depression. It has been reported that α2-adrenergic autoreceptors are hyperactive 
in major depression (Garcia-Sevilla et al., 1999), which may lead to a decrease of 
both noradrenergic and serotonergic neurotransmission. TCAs have been shown to 
desensitise α2-adrenergic autoreceptors, and may thus be capable of normalizing 
the alleged disrupted monoaminergic transmission in depression (Mateo et al., 
2001).  
Preclinical evidence regarding 5-HT receptor subtypes is not very consistent. In 
fact desensitization has only been convincingly shown for the 5-HT1A autoreceptor, 
however not all antidepressants are capable of desensitizing this receptor following 
chronic treatment (Hjorth & Auerbach, 1994). 
Dopamine receptors have received relatively little attention in antidepressant 
research compared to serotonin and noradrenaline. Traditionally, dopamine 
research was targeted at other fields of psychiatry such as schizophrenia, 
obsessive-compulsive disorder and addiction but also at neurological disorders 
such as Parkinson’s and Huntington’s disease. In European countries the dopamine 
reuptake inhibitor bupropion is prescribed to diminish nicotine craving, however in 
the USA the compound is registered as an antidepressant. A recent study indicates 
that antidepressant efficacies of bupropion and venlafaxine, a dual serotonin and 
noradrenaline reuptake inhibitor, are comparable (Hewett et al., 2008). 
Postsynaptic D2 receptors may be hypersensitive in depression, although this idea 
is primarily based on behavioral studies in laboratory animals following chronic 
antidepressant treatment (Maj et al., 1996; Spyraki & Fibiger, 1981). Typical 
antipsychotics such as dopamine D2 receptor antagonists may also have 
antidepressant efficacy (Ruther et al., 1999). Moreover, the atypical antipsychotic 
amisulpride was shown to have antidepressant efficacy, which was attributed to a 
preferential blockade of presynaptic D3 dopamine receptors, leading to an 
increased dopamine release (Racagni et al., 2004). Accordingly, several 
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albeit with varying success rates (Montgomery, 2008). Several compounds 
combining SSRI and partial dopamine D2 agonist activity in one molecule are 
currently under investigation (Michael-Titus et al., 2008). 
The general hypothesis remains that deficiencies in dopamine, serotonin and 
norepinephrine underlie the pathology of major depressive disorder (Nutt, 2006). 
However, in spite of the adaptations made to the monoamine hypothesis and its 
usefulness in developing more or less effective antidepressants, it remains 
questionable whether this hypothesis adequately reflects the underlying pathology 
of affective disorders. It is clear that other hypotheses also have to be considered 
(Krishnan & Nestler, 2008). 
1.1.2   The HPA-axis hypothesis/stress induced dysfunction 
1.1.2.1   The role of Stress 
The role of stress hypothalamic-pituitary-adrenal axis (HPA-axis) hyperactivity in 
psychiatric disorders is well established. The initiator of stress research is Hans 
Selye, who described stress as a syndrome produced by various noxious agents 
(Selye, 1936). His paper in Nature is considered to be the starting point of stress 
research, which has finally resulted in the elucidation of HPA-axis functioning. 
Seyle states that “stress is the state manifested by a specific syndrome which 
consists of all the non-specifically induced changes within a biologic system” 
(Selye, 1985). The stress syndrome can be induced by all kind of stressors with 
individual vulnerability playing an important role. It is believed that prolonged 
exposure to stressors leads to the stress syndrome. Based on Selye’s and many 
other observations, it is no surprise that a connection with affective disorders was 
made. Strong evidence over the years has linked failure to cope with stressful 
events to the etiology of depressive disorders (Kendler et al., 1999; Hammen, 
2005).  
1.1.2.2   The role of the HPA-axis 
The HPA-axis is the communication system that prepares the body for the so- 
called fight, fright and flight response. The body has to be prepared to respond to 
stressful situations. First, the sympathetic adrenal medullary (SAM) system is 
activated, which results in an increased release of adrenaline and noradrenaline 
from the adrenals and sympathetic nerve terminals, respectively. In the secondary 
phase, corticotrophin-releasing hormone (CRH) is released by the hypothalamus. 
CRH stimulates the excretion of adrenocorticotrophin (ACTH) from the pituitary 
(Bale & Vale, 2004). This hormone is released into the bloodstream and 
transported to the adrenals, where it stimulates the excretion of corticosteroids 
(cortisol in primates and corticosterone in rodents) (Charmandari et al., 2005). 
Under normal conditions, HPA-axis activity is regulated by several negative 
feedback mechanisms. Briefly, ACTH exerts a negative feedback control on the 
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release of CRH, whereas cortisol exerts a negative feedback control on both the 
release of ACTH and CRH. This returns the body from the activated to a more 
normalized state and prevents overexposure to cortisol. In the short term cortisol 
is essential for the body to cope with acute stressors, however it is believed that 
sustained elevation of cortisol will lead to severe physiological dysfunctions 
(Sapolsky et al., 2000). For instance, during constant activation of the pituitary and 
adrenals, these glands become enlarged. Moreover, the constant activation of 
certain target areas by cortisol may eventually lead to tissue damage; for example, 
in the hippocampus, where transcription of certain genes is halted by the 
glucocorticoid receptor (GR) and dendritic retraction occurs (Kole et al., 2004; 
Sapolsky, 2000). Other physiological functions, like the immune responses are also 
impaired by a continuous activation of the HPA-axis. Some authors have even 
suggested that exposure to a single severe stressful event has life-long 
implications (Koolhaas et al., 1997). 
1.1.2.2.1 HPA-axis and depression 
Several observations support an involvement of HPA-axis dysfunction in depression 
(Pariante & Lightman, 2008). A number of patients experiencing depression 
excrete significantly more cortisol after stimulation with corticotrophin releasing 
hormone (CRH) (Gold et al., 1986a; Gold et al., 1986b). This hormonal release 
pattern occurs in approximately 50% of patients with a major depressive disorder 
(Maes et al., 1990; Holsboer, 2000). Enlargements of the pituitary and adrenal 
glands have been shown in depressed patients, also indicating a hyperactive HPA-
axis (Owens & Nemeroff, 1993; Gold et al., 1986a). It has also been shown that 
depressed patients display a blunted ACTH response to CRH administration 
(Nemeroff, 1996; Gold et al., 1986a). Finally, postmortem studies of suicide victims 
have shown increased CRH values in cerebrospinal fluid (CSF) and a decreased 
CRH receptor density in the brain (Arato et al., 1989; Nemeroff et al., 1984), as 
well as reduced mineralocorticoid receptor (MR) (Lopez et al., 1998). 
1.1.2.3   The role of corticoid receptors 
Occupation of MR and GR receptors by cortisol is an important factor in the 
regulation of HPA axis activity (Reul & De Kloet, 1985; McEwen et al., 1986). In 
particular the correct balance of MR and GR mediated effects may be vital to 
restrain HPA activity (De Kloet et al., 1998). An imbalance in MR/GR actions may 
lead to alterations in the behavioral adaptation necessary to normalize the stress 
response. When the MR/GR imbalance persists and surpasses a predisposed 
individual threshold, cognition is compromised and vulnerability for developing 
affective disorders may also increase (De Kloet et al., 1998; De Kloet et al., 1999). 
Importantly, the time course of antidepressant-induced corticoid receptor up-
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clinical improvement of depression (Reul et al., 1993; Reul et al., 1994; Yu et al., 
2008). 
1.1.2.4   The role of CRH 
It has been proposed that increased CRH plays a role in the pathogenesis of 
depression (Raadsheer et al., 1994; Nemeroff, 1988). Accordingly, it has been 
postulated that any intervention restoring HPA dysfunction may have an 
antidepressant effect (Nestler, 1998). Additional support for the stress/HPA-axis 
hypothesis is derived from the observation that depressive episodes follow 
traumatic life events. Such stressful life events are characterized by chronic 
activation of the HPA-axis. This might lead to changes in GR and MR density and 
also an impaired GR/MR balance, eventually resulting in HPA-axis dysfunction. 
Using the dexamethasone/CRH suppression test, both in depressed patients and in 
their non-depressed relatives showed a blunted cortisol response in both groups. 
The study suggested that genes play a role in the vulnerability for stress (Holsboer 
et al., 1995). On the other hand, the study also showed that a dysfunctional HPA-
axis does not lead to an affective disorder per se. Yet, it is clear that the HPA-axis 
plays a role in the etiology and treatment of affective disorders (Ising et al., 2005). 
1.1.2.5   HPA-axis and 5-HT 
There is extensive pharmacological and neuro-anatomical evidence that 5-HT 
containing neurons regulate the HPA-axis in rats (Fuller & Snoddy, 1990). 
Serotonergic neurotransmission has an excitatory influence on HPA-axis activity. 
For instance, local application of serotonin dose-dependently increases CRH in the 
hypothalamus (Holmes et al., 1982). Serotonin directly stimulates the release of 
ACTH from the pituitary (Spinedi & Negro-Vilar, 1983). Moreover, serotonin 
increases corticosteroid receptor densities in hippocampus through 5-HT1A 
receptors (Budziszewska et al., 1995). Thus the serotonergic system influences 
HPA-axis feedback mechanisms at different levels. 
Vice versa, the HPA-axis influences serotonergic neurotransmission. For instance 
corticosteroids influence 5-HT synthesis through the enzyme tryptophan 
hydroxylase, thereby affecting 5-HT turnover but not 5-HT levels (Azmitia, Jr. & 
McEwen, 1969; Azmitia, Jr. et al., 1970). It has also been reported that local 
application of GR receptor agonists into the dorsal raphe nucleus compromises the 
functioning of the 5-HT1A autoreceptor (Laaris et al., 1995). Furthermore, 
normalization of HPA-axis after antidepressant treatment may be due to 
antidepressant-induced changes in brain corticoid receptor capacity (Barden et al., 
1995). This normalization of HPA-axis activity is likely to be related to a restoration 
of the negative feedback between corticosteroids and the HPA-axis, possibly via 
increased corticosteroid receptor gene expression. Thus, non-suppression of 
dexamethasone in patients with depression disappears after recovery, and 
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normalisation of the HPA-axis is considered essential for permanent improvement 
(Ribeiro et al., 1993; Firk & Markus, 2007). 
1.1.3   Neuroplasticity hypothesis 
Antidepressants immediately increase extracellular monoamine levels in the brain, 
yet their therapeutic effect is delayed for several weeks. The hypothesis that a 
simple shortage of monoamines would explain the etiology of major depression is 
therefore rather unlikely. Consequently, it has been proposed that adaptations 
have to take place to facilitate the therapeutic effect of antidepressants. Advances 
in both clinical and preclinical research have led to the proposition that 
neuroplasticity plays an important role in both the etiology and treatment of 
affective disorders. 
The neuroplasticity hypothesis states that major depression results from an 
inability of the organism to make appropriate adaptive responses to stress or other 
aversive stimuli (Duman et al., 1999). These inabilities could indicate an impaired 
capacity of the brain to correctly process such stimuli. In other words, the brain 
may have become rigid and according to this hypothesis, depressed. 
Several studies support the idea that the integrity of the brain is affected in major 
depressive disorders. Neuroimaging studies, for example, have demonstrated a 
reduced gray-matter volume in the prefrontal cortex (PFC) and striatum of 
depressed patients. Furthermore, enlargements of the third ventricle have been 
reported in patients, that were compared to healthy volunteers (Drevets, 2000). 
Neuropathological studies in post-mortem tissue from depressed patients also 
showed a reduction of cortical volume. In addition, glia cell count was reduced as 
well as neuron size in the PFC and amygdala (Rajkowska et al., 1999; Rajkowska, 
2000). Reduced glial density and glia to neuron ratios in the amygdala have also 
been reported (Hamidi et al., 2004). Notably, glial cells play a critical role in 
regulating synaptic glutamate concentration, central nervous system (CNS) 
homeostasis and in the release of trophic factors (Araque et al., 2000;Ullian et al., 
2004) 
1.1.3.1   Neurogenesis 
There is a growing body of preclinical evidence in support of the neuroplasticity 
hypothesis. Gould and colleagues made a real advance, showing that against all 
expectations neurogenesis occurs in the adult brain. First, this was shown in 
rodents and non-human primates, but more recently it was also shown in humans 
(Gould et al., 1997; Eriksson et al., 1998). Next, it was demonstrated that stress 
reduced neurogenesis in scadentia, a species phylogenetically in between 
insectivores and primates, and in primates (Gould et al., 1997; Gould et al., 1998). 
Conversely, neurogenesis is stimulated in rodents placed in a rich environment 
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subsequently trained to perform an associative learning task, the survival rate of 
the newly formed cells increased (Gould et al., 1999). During stress, apoptosis or 
cell death appeared to be increased. The effects were region specific, but not 
restricted to the granular cell layer in the dentate gyrus of the hippocampus 
(Lucassen et al., 2001).  
These observations imply that: 
• The adult brain is capable of creating new neurons and other 
cells. 
• The process of neurogenesis and cell survival can be 
influenced by various environmental stimuli. 
• Neurogenesis combined with apoptosis may represent a 
flexible system, which has evolved to enable adaptation of 
the organism to changing environmental conditions. 
• This system of flexibility is apparently compromised by 
chronic stress. 
 
Different types of antidepressant treatment also appear to influence neurogenesis. 
For example, electroconvulsive shock treatment of animals was shown to have a 
positive effect on neuropeptide system plasticity (Altar et al., 2004). It has also 
been shown that electric convulsive therapy (ECT) induces neurogenesis and that 
antidepressants stimulate cytogenesis (Madsen et al., 2000; Malberg et al., 2000). 
The general consensus is now that the stressed/depressed brain is maladaptive, 
implying that the organism is less capable to adapt and react to external stimuli. It 
is probably this state of the brain, which causes depression. There is compelling 
evidence that the reduced neurogenis observed in several animals models can be 
reversed by antidepressants (Dranovsky & Hen, 2006). And it could be that 
stimulation of the hippocampal neurogenesis is part of the therapeutic effect of 
antidepressant drugs (Sahay & Hen, 2007). The lack of neuroplasticity might also 
offer a viable explanation for the co-occurrence of affective disorders with such 
neurodegenerative disorders as Parkinson’s disease.  
1.1.3.2   Synaptic plasticity 
As mentioned previously, glial function is compromised in depressed patients. Glia 
cells are mostly thought of for having a supportive role for neurons and as playing 
a role in synaptic activity. In the adult mammalian brain glial cells outnumber 
neurons by a factor 10-15. In the brain 3 types of glial cells can be found; 
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microglial cells, oligodendrocytes and astrocytes. Microglial cells are small cells of 
distinct shape. When activated they play a major role in immunological protection 
of the brain. Oligodendrites are involved in axon isolation and signal transduction, 
a function similar to the Schwann cells in the peripheral nervous system. 
Astrocytes are the most abundant glial cell type in the brain. They are found in 
close association with axons, blood capillaries and cell bodies. Several essential 
functions have been attributed to these cells such as, the supply of energy and 
nutrients to neurons, neurotransmitter metabolism, maintenance of ion 
homeostasis in the extracellular space, regulation of neuronal migration, secretion 
of growth factors and participation in immune and inflammatory responses. 
Because of their close association with the blood capillaries, they are a vital part of 
the blood-brain-barrier (BBB). Astrocytes also possess receptors for 
neurotransmitters and steroid hormones, that can trigger electrical and biochemical 
events inside the cell, comparable to neurons. Astrocytes can release glutamate 
and d-serine, enabling them to modulate neuronal activity. 
Moreover, astrocytes influence both synaptogenesis and synaptic transmission. A 
recent study in chronically stressed tree shrews has demonstrated a reduction in 
the number astrocytes expressing glial fibrillary acidic protein (GFAP, a cytoskelatal 
protein) as well as a decreased cell body volume. Glial cells also play an important 
role in synaptic function (Barres, 2008). In the CA1 hippocampal area a single 
astrocyte can contact with up to 140,000 synapses (Bushong et al., 2002). In this 
specific region about 60% of mainly glutamatergic synapses have intimate contact 
with surrounding astrocytes (Ventura & Harris, 1999). Astrocytes influence 
neuronal morphology in two ways: first, by releasing compounds that enhance 
synaptic transmission, such as d-serine, which acts as co-agonist of the NMDA 
receptor. Second, by releasing factors, that influence axonal and dendritic 
outgrowth, and thus the number of synaptic connections (Ullian et al., 
2004;Pittenger et al., 2007). 
Chronic stress has a major impact on the shape of dendrites in the hippocampal 
formation. It has been reported that the shape of the dendrites influences the 
firing rate of neurons (van Ooyen et al., 2002). Magarinos (1996) has shown that 
chronic stress leads to dendritic retraction of the pyramidal cell in the CA3 area of 
the hippocampus (Magarinos et al., 1996). This retraction of dendritic outgrowth 
was found with various stress paradigms, and may lead to a reduction of effective 
synapses. When animals are housed in a stimulatory environment the opposite 
occurs and increased synapse formation and an increased length of the dendrites 
are observed (van Praag et al., 2000). 
The volume loss observed in the brains of depressed patients could be related to 
stress. In animal studies it has been shown that hippocampal volume is reduced 
after chronic stress. It has been suggested that a hyperactive HPA-axis is 
responsible for this volume loss. However, this volume loss could not be induced 
by hypercortisolemia (Sousa et al., 2000; Leverenz et al., 1999). Moreover, the 
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in severely depressed patients or patients chronically treated with steroid 
hormones such as prednisolone (Muller et al., 2001). An alternative explanation for 
the loss of brain volume could be a reduction of extracellular space (ECS) (Sykova 
& Chvatal, 2000). The ECS of the central nervous system is the microenvironment 
of neurons and glial cells and its composition and size changes during neuronal 
activity. Suggestions have been made that the volume of the ECS might be 
compromised during pathological states of the brain. One must realize that this is 
relatively unknown territory, which deserves further investigation. 
1.1.3.3   Intracellular Plasticity 
The alleged compromised neuroplasticity in affective disorders may involve 
changes at different cellular levels. For example changes of the cAMP cascades 
have been reported by several groups (Perez et al., 2000;Perez et al., 1989;Ozawa 
& Rasenick, 1991). Also cAMP response element binding protein (CREB), a 
transcription factor that mediates many of the actions of cAMP, is up-regulated by 
chronic, but not acute antidepressant treatment (Nibuya et al., 1996). In addition, 
a post-mortem study has shown that expression of CREB is decreased in the 
temporal cortex of patients with depression, whereas antidepressant treatment 
was shown to reverse this effect (Dowlatshahi et al., 1998). Chronic antidepressant 
treatment not only increased percentage of phosphorylated state of CREB proteins, 
but it also increased the expression levels of brain derived neurotrophic factor 
(BDNF), a major gene target regulated by CREB (Duman, 2002). BDNF belongs to 
the family of neurotrophic factors, which also includes the nerve growth factors 
neurotrophin 3 and 4 (Thoenen, 1995). Initially neurotrophic factors were being 
characterized for regulating neuronal growth and differentiation during 
development, but now they are also recognized as potent regulators of synaptic 
plasticity and survival of adult neurons and glia (Patterson et al., 1996;Korte et al., 
1996). 
1.2   Affective disorders and the immune system 
Previously, we have focused primarily on the central nervous system, but immune 
function is playing an important role in affective disorders too. 
The involvement of the immune system in affective disorders is well known. For 
instance, patients treated with interleukin-1 develop depressive-like symptoms, like 
disturbances in circadian rhythm as witnessed by an altered sleep/wake cycle. 
Depressed patients are also more susceptible to infections, allergies and 
autoimmune diseases (Whitlock & Sisking, 1979). This so-called sickness behavior 
suggests impairments of immune system function. Antidepressant treatment does 
not only alleviate symptoms of depression, but it also improves immune system 
function (Castanon et al., 2002).  
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Several lines of evidence indicate that central nervous system (CNS) and immune 
system interact. For instance, sympathetic nerve endings were shown to be 
present in lymphoid tissue. Also, cytokinine receptors have been found on CNS 
neurons, amongst others in brain structures that are associated with depression, 
such as hypothalamus, hippocampus and locus coeruleus (Turnbull & Rivier, 1999). 
Moreover, activated T cells and monocytes can pass the blood brain barrier and 
bind to brain cells through cell-membrane specific molecules (Maes et al., 1995).  
The presence of monoamine receptors on lymphocytes and the production of HPA-
axis mediators such as ACTH by lymphocytes suggest a direct communication 
between CNS and immune system during stressful events. It has been reported 
that (large) increases of cortisol levels are capable of inducing thymocyte apoptosis 
(van den Brandt et al., 2007). Social defeat in rats results in more persistent 
alterations of thymus function (Engler & Stefanski, 2003). Moreover, both surgical 
and physical stress suppresses the activation of natural killer (NK) cells in rats (Ben 
Eliyahu et al., 1999).  
Several studies have been performed in vitro to investigate the effect of 
antidepressants on the immune system, for instance, by testing the proliferation 
rate of isolated lymphocytes under different antidepressant treatment regimes. It 
appeared that all tested antidepressants dose-dependently reduced the capacity of 
lymphocytes to proliferate in response to lectin or antigen activation (Castanon et 
al., 2002).  
1.3   Animal models of affective disorders 
Studying the mechanisms underlying affective disorders in humans has many 
restrictions. Invasive techniques for the brain are not allowed and ethical 
considerations limit the use of psychological trauma models that are indispensable 
for inducing pathological effects reminiscent of those in major depression.  
For this reason animal models have been developed to study the biological 
processes implicated in major depression (Shively, 1998). Such animal models 
must fulfil three important criteria viz. high face-, construct- and predictive-validity. 
High face-validity is achieved when a model replicates several of the symptoms 
seen in depressed patients, such as anhedonia and low locomotor activity. A model 
has high construct-validity when it is homologous in etiology and has an empirical 
and theoretical relationship to the disorder. Finally, having a high predictive-
validity, means that the animal model is capable of correctly identifying efficacious 
pharmacotherapy. For major depression this implies that the behavioral correlates 
of the animal model must respond to chronic antidepressant treatment. As yet, no 
animal model has been able to unambiguously meet all these three criteria. 
Animal models for depression can be divided in two groups. The first group is more 
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features, which can be specifically influenced by antidepressants. The second 
group is based on etiological considerations, such as the notion that stressful life 
events are among the most potent triggers of a depressive episode (Kendler et al., 
1999). In the next sections examples of both types of animal models will be given, 
although more animal models have been developed over the years (McArthur & 
Borsini, 2006). 
1.3.1   Animal models based on observations 
In the learned helplessness paradigm animals are exposed to aversive stimuli, 
which they cannot predict, control or avoid (Seligman & Beagley, 1975). In this 
model the animal shows deficits in escape performance, but also decreased 
locomotor activity and a loss of appetite and weight. Treatment with 
antidepressants is capable of reversing these symptoms (Willner et al., 1992;Yadid 
et al., 2000) 
In the Porsolt swim test (Porsolt et al., 1977), also known as the forced swim test, 
a rat or a mouse is placed in a container filled with water from which it cannot 
escape. After some time the animal knows that it is useless to struggle, and it 
assumes an immobile posture. When placed for a second time in the container the 
period of struggling is shorter and the animal takes on its immobile posture more 
rapidly. The onset of this immobility is delayed by pre-treatment with 
antidepressants (Kawashima et al., 1986). 
In the chronic unpredictable stress paradigm (Katz, 1981) the animal is 
subsequently exposed to various kinds of stressors. This results in disrupted 
behavior in the open field test, which measures explorative behavior of the animal. 
Treatment with antidepressants during the chronic stress period was shown to 
prevent the aberrant behavior in the open field. The paradigm exists in several 
variations and is also known as the chronic mild stress model of depression (Papp 
et al., 2002) 
The animal models in this section are often used by the pharmaceutical companies 
in the screening process of new potential antidepressants (for a more elaborate 
overview see (Bourin et al., 2001).  
1.3.2   Animal models based on etiology 
Animal models based on etiology mostly refer to the notion that a stressful life 
event is likely to increase susceptibility for affective disorders. As the etiology for 
depression is still not clear, several models have been developed based on the 
assumption that stress plays a major factor in developing depression. Although the 









Compleet 18 mei.doc 
 
Introduction 
Prenatal stress exists of inflicting stressful stimuli to pregnant rats, such as 
repeated restraint stress for 30 minutes. Fride (1986) demonstrated that the 
offspring of these rats showed reduced stress coping abilities and an increased 
emotionality, as witnessed by an increased anxious reaction in fear related tests 
(Fride et al., 1986). Furthermore HPA-axis response to stressful stimuli in the 
offspring was more profound (Bhatnagar et al., 2005; Coe et al., 2003). 
Maternal separation is based on removing the pups for a variable period of time 
from their mother during the weaning period. These pups show a long-lasting HPA-
axis response to stress. Deficits in attention and emotions were also reported, but 
not in all studies. Sometimes the opposite effect was noted which according to 
Staton et al. (1988) might relate to the time point of maternal deprivation (Stanton 
& Levine, 1988; Millstein & Holmes, 2007). 
Social defeat models refer to the increased risk for developing an affective disorder 
when humans lose their social status (Brown et al., 1990). Many species have a 
strong hierarchical social structure, primarily based on confrontations between 
males. Loss of rank within such hierarchical structure may model the loss of social 
status in humans. It has been proposed that the loss of rank in animals in an 
established social group might serve as model for loss of self-esteem in humans, 
which could lead to depression (Willner, 1995; Rygula et al., 2008) 
Primates live in hierarchal structures, and social status is of eminent importance for 
reproduction, food intake and other privileges. It appears that basal cortisol levels 
are correlated with the social status of an individual within the group. For example 
dominant squirrel monkeys in captivity have significantly lower levels of cortisol 
(Manogue et al., 1975). High-ranking male olive baboons living in the wild also 
showed lower plasma cortisol levels, and a stronger cortisol response during 
stressful encounters (Sapolsky, 1982). However, markedly increased basal cortisol 
levels were measured in higher ranked males when their authority was 
compromised during social instability. This rise in basal cortisol levels was not only 
seen in the higher ranked animals, but occasionally also in lower ranked animals 
involved in the social instability. Apparently individual coping styles determine HPA-
axis reaction during social instability and hence the physiological consequences of 
this hypercortisolism (Sapolsky, 1994; Shively et al., 2006). 
Several animal models are based on social defeat. For example the resident 
intruder paradigm, which has been developed for several species but is most 
investigated in rats. Social defeat elicits long lasting behavioral and physiological 
changes in rats, however, these effects can be prevented by chronic 
antidepressant treatment (Koolhaas et al., 1990; Rygula et al., 2008). 
Variations of the resident intruder paradigm are also used in mice and tree shrews 
(Fuchs & Flugge, 2002). The tree shrew variant will be discussed in more 
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1.4   Neuropeptides and affective disorders  
Despite major advances in biological research in the past decades, no revolutionary 
new therapies to treat affective disorders have emerged. New generations of 
antidepressants still have to be administered over an extended period of time 
before any therapeutic effect can be observed. Also antidepressant treatment is 
still associated with undesirable side effects, often leading to discontinuation of 
treatment. 
Research may not have led to major breakthroughs in pharmacotherapy, but it has 
sharpened the insights in the processes and the brain areas, that play a role in 
affective disorders. Here we will discuss neuropeptides and their (neuro-) 
modulatory role in brain areas allegedly involved in affective disorders such as 
hypothalamus, amygdala, peri-aquaductal gray (PAG) and hippocampus. 
1.4.1   Neuropeptides 
The neuropeptides form a steadily growing group of more than 50 endogenous 
compounds with a broad spectrum of biological effects. Neuropeptides are 
conserved between species and can be subdivided into families. Some 
neuropeptides are associated with rather distinct behaviors. For example, oxytocin 
and vasopressin have striking and specific effects on social behaviour, including 
maternal behavior and pair bonding. Other well-known peptides are 
cholecystokinin, dynorphin, substance P and neuropeptide Y.  
 
1.4.1.1   Function 
Neuropeptides interact with G-protein-coupled receptors (also called: metabotrobic 
receptors), which are expressed by selective populations of neurons. Their 
chemical structure consists of 4 to 131 amino acid residues and distribution 
throughout the body is widespread. They function as molecular messengers 
between neurons, thereby influencing the neuron excitability through a process of 
depolarisation or hyperpolarisation, a property they have in common with classical 
neutransmitters, such as dopamine, noradrenaline and serotonine. However, 
neuropeptides can have divergent effects, such as modulation of gene expression, 
local blood flow, synaptogenesis, and glial cell morphology. 
1.4.1.2   Neuropeptides versus ‘classical’ neurotransmitters 
Many neurons are capable of making both a ‘classical’ neurotransmitter (such as 
glutamate, GABA or dopamine) and one or more neuropeptides. However, storage 
and release of these latter chemical messengers differs from ‘classical’ 
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neurotransmitters which are reflected at their functional level. For instance, the 
large dense vesicles (LDVs), in which neuropeptides are stored, are more sensitive 
to local intracellular calcium variations, leading to a more subtle release 
mechanism in comparison with the classical neurotransmitters (De Camilli, 1991). 
Release of the latter is according to a kind of ‘go or no-go’ principle. When a 
certain threshold is reached, exocytosis is a fact, while with neuropeptides release 
is generally more gradual. Neuropeptides and ‘classical’ neurotransmitters also 
display major differences in synthesis. Neuropeptides are synthesized at the 
endoplasmatic reticulum as pro-peptides, which must be spliced first by enzymes in 
order to become the bioactive neuropeptide. This splicing takes place during 
axonal transport and the neuropeptides are subsequently stored in LDVs (Hokfelt 
et al., 2000; Hokfelt et al., 2001). In contrast, classical neurotransmitters are 
synthesized by enzymes from amino acids readily available in the body and in case 
of serotonin from dietary tryptophan. Biosynthesis can take place at the release 
site, thereby avoiding the time consuming process of axonal transport (Sulzer et 
al., 2005). After synthesis, ‘classical’ neurotransmitters are stored in small synaptic 
vesicles (SSVs). Because LDVs are 10 times more sensitive to elevations of the 
intracellular calcium concentration than SSVs, neuropeptides may serve to fine-
tune the action of classical neurotransmitters (De Camilli, 1991). This increased 
sensitivity of the LDVs for calcium is likely to be related to the activity of a voltage 
dependant L-type calcium channels (tue-Ferrer et al., 1993). When these channels 
are specifically blocked, both the electrical and potassium evoked release of 
substance P is inhibited (Holz et al., 1988). Blockade of L-type calcium channels 
does, however, not inhibit potassium-evoked release of noradrenaline, indicating 
that the release of neuropeptides is regulated differently compared to ‘classical’ 
neurotransmitter release (Perney et al., 1986). LDVs are distributed throughout the 
neuron, including soma, dendrites, axonal swellings and nerve endings, whereas 
the SSVs are mainly clustered at synaptic junctions. Another major difference 
between classical neurotransmitters and neuropeptides is in the duration of 
neurotransmission, which are milliseconds versus minutes, respectively. This 
difference may be related to the time needed to remove the transmitter from the 
target area. Monoaminergic neurons possess a highly efficient reuptake mechanism 
and the enzymes responsible for the degradation of monoamines viz. catechol-O-
methyl transferase (COMT) and mono amine oxidase (MAO) are present in 
abundance (Bortolato et al., 2008). Except for cholecystokinin (CCK) a reuptake 
mechanism for neuropeptides has not been demonstrated yet. Moreover, 
neuropeptides are inactivated through several steps of enzymatic degradation. For 
instance, substance P is inactivated by endopeptidases, ACE and aminopeptidases, 
but sometimes a second enzymatic degradation step is required to fully inactivate 
substance P (Michael-Titus et al., 2002). De novo-synthesis of the neuropeptides is 
also a limiting factor, because they have to be synthesized at the endoplasmatic 
reticulum as pro-peptide, transported from the endoplasmatic reticulum to the 
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1.4.1.3   Extrasynaptic transmission 
The prolonged action of neuropeptides might imply a more modulating role 
reminiscent of hormonal function. Accordingly, neuropeptides may play a role in 
paracrine transmission, also referred to as volume or extrasynaptic transmission 
(Fuxe et al., 1996; Vizi et al., 2004). The predominant extrasynaptic location of 
neuropeptides and the notion that release sites of neuropeptides do not always 
face the target receptors are equally in support of a paracrine-like function.  
1.4.1.4   Interactions between neuropeptides and monoamine neurotransmitters 
Interactions between neuropeptides and ‘classical’ neurotransmitters can take 
different forms. First, as main transmitters of peptidergic neurons they can activate 
specific receptors located on axon terminals of glutamatergic or GABA-ergic 
neurons. In this way neuropeptides may fine-tune the effects of these major 
excitatory and inhibitory neurotransmitters on monoaminergic systems, the prime 
targets of antidepressants. Examples are the regulation of 5-HT release in dorsal 
raphe nucleus by CRH through GABA and substance P via glutamate. Second, 
neuropeptides may be co-localized with monoamines. An interesting example is 5-
HT moduline, a peptide strongly associated with the function of 5-HT1B receptors. 
Deactivation of 5-HT moduline by selective antibodies has anxiolytic-like activity in 
mice as assessed in the open field and elevated plus maze tests (Fillion et al., 
1996; Moret & Briley, 2000). It is clear from these examples that neuropeptides 
modulate monoaminergic transmission. Therefore, interfering with ex- and intrinsic 
neuropeptidergic processes may have antidepressant/anxiolytic potential (Holmes 
et al., 2003). Prime examples are cortorticotrophin releasing hormone (CRH), 
oxytocin (OXT) and arginine-vasopressin (AVP) and substance P.  
1.4.1.5   Corticotrophin releasing hormone 
The neuropeptide CRH has been implicated in affective disorders in two ways. 
Firstly, CRH plays a crucial role in the regulation of HPA-axis activity. It is released 
from the paraventricular nucleus (PVN) into the hypothalamo-hypophyseal portal 
vessels, where it stimulates ACTH release from the anterior pituitary, which 
eventually leads to the release of cortisol from the adrenals. Release of CRH is also 
subject to feedback regulation controlling HPA-axis activity. Infusion of CRH 
fragments into the brain of rodents leads to anxious behavior and HPA-axis 
dysfunction. Evidence has been presented that unrestrained secretion of CRH in 
the central nervous system induces depressive symptoms by activating CRH1 
receptors continuously. All currently known antidepressants restore the negative 
feedback between corticosteroids and the HPA-axis, possibly by increasing 
corticosteroid receptor gene expression. Notably, in an open-label safety study the 
CRH1 receptor antagonist R121919 significantly reduced depression and anxiety 
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scores, however not with a faster onset of action than regular antidepressants 
(Zobel et al., 2000). 
The second way is implied in affective disorders, which involves the CRH neuronal 
circuitry in the brain. The CRH neuronal pathway originates in the amygdale, 
projecting to the bed nucleus of the stria terminalis (BNST), the PAG, dorsal raphe 
nucleus (DRN) and locus coerulus (LC). The latter two brain areas contain the 
majority of serotonergic and noradrenergic cell bodies, respectively. Arguably, 
regulation of monoaminergic activity by CRH embeds the peptide in the 
monoamine hypothesis of depression. In particular interactions between CRH and 
5-HT in dorsal raphe nucleus may be of interest in the pathophysiology of 
depression, as witnessed by the increased CRH immunoreactivity in dorsal raphe 
nucleus of depressed suicide victims. Valentino and Commons suggested that 5-HT 
neuronal activity in dorsal raphe nucleus is controlled by CRH1 and CRH2 receptors 
via opposite actions on GABA (Valentino & Commons, 2005). According to these 
authors, the abundant expression in dorsal raphe nucleus of NK1 receptors in the 
vicinity of neurons that co-localize 5-HT and CRH suggests that the dorsal raphe 
nucleus is an important locus for 5-HT-CRH-NK interactions. These interactions 
could play a role in the anxiolytic-like activity of NK1 receptor antagonists through 
inhibition of CRH/5-HT neurons that project from dorsal raphe nucleus to the 
central nucleus of the amygdala. 
Based on their observations Valentino and Commons suggest that combining 
classic antidepressants with CRH1 and NK1 receptor antagonists might help to 
individualize and optimize efficacy and minimize side effects of treatment 
(Valentino & Commons, 2005). 
1.4.1.6   Oxytocin and arginine-vasopressin 
The neuropeptides oxytocin and arginine vasopressin (AVP) are produced in the 
supraoptic and paraventricular nucleus (PVN) of the hypothalamus. Peripheral 
release is via pituitary projections to the neuro-hypophysis. However, oxytocin and 
AVP are also directed centrally into the brain (Landgraf & Neumann, 2004). Both 
oxytocin and AVP are long acting neuron-modulators, and in addition to their 
peripheral functions they may be involved in stress responses, learning and 
memory. Furthermore, AVP is co-localized with CRH. In animal models oxytocin 
has anxiolytic-like effects while AVP has anxiogenic effects (Landgraf, 2006). A 
recent study has shown that the CRH1 receptor antagonist SSR125543A, the V1b 
AVP receptor antagonist SSR149415 and the clinically effective antidepressant 
fluoxetine all reverse chronic mild stress induced suppression of neurogenesis in 
mice. It is likely that reversal in neurogenisis is cased by increased expression of 
the cAMP response element-binding protein (CREB) in dentate gyrus (Alonso et al., 
2004; Stemmelin et al., 2005). Both oxytocin and AVP have been implicated in 
obsessive behaviors and depression. Postmortem analysis of brain tissue from 
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immunoreactive neurons in the PVN (Swaab et al., 2005). Plasma levels of AVP in 
depression (especially in patients with melancholic type) were higher than normal, 
while no differences were observed for oxytocin levels, although there was a 
tendency to increased levels. Oxytocin and its precursor molecule have been 
associated with clinical response to electro-convulsive shock therapy (ECT), which 
could however not be replicated by others (Smith et al., 1994; Devanand et al., 
1998). Yet, both clinical and preclinical studies suggest a role for oxytocin as an 
endogenous antidepressant (Rosat Consiglio, 2006). Acute as well as chronic 
administration of SSRIs increases blood oxytocin levels in rats. These observations 
suggest that antidepressant treatment could be capable of normalizing the 
decreased oxytocin plasma levels in depressed patients (Uvnas-Moberg et al., 
1999). 
1.5   Substance P 
The neurokinin substance P, first known for its involvement in nociception, has 
been the subject of renewed interest since it was discovered that neurokinin 1 
antagonists possess antidepressant properties. It is also the main subject of this 
thesis. And will therefore be discussed in more detail 
1.5.1   History of substance P 
In 1931 von Euler described, an atropine resistant substance, from the gastro-
intestinal tract of rabbits in the Journal of Physiology. He named this unidentified 
compound substance P and suggested that it could be found in the brain as well. 
Pernow, a student of Von Euler, continued his work on substance P. He purified 
the substance and was able to elucidate the distribution of substance P in the 
spinal cord, the brain and the regional distribution within these areas. He also 
demonstrated the neuronal localization of substance P. At the same time a group 
in Austria under supervision of Lembeck presented convincing evidence that 
substance P is a sensory neurotransmitter. It was not until the early seventies that 
Leeman and colleagues identified substance P as an undecapeptide. Her group was 
also the first to synthesise substance P and to set-up a radioimmunoassay for the 
peptide. This enabled functional and immuno-histochemical studies. Finally, it was 
also possible to measure the release of substance P, which turned out to fulfill 
several important criteria of neurotransmitter release. It was now possible to 
describe the role of the peptide in spinal cord pain transmission in more detail, 














1.5.2   Biochemistry of substance P  
Substance P is synthesized from preprotachykinin-A. This pro-peptide can be 
cleaved in 4 ways resulting in substance P alone; a combination of substance P, 
NK-A and NPK; or substance P, NK-A and NP-Y. Thus maturation of the pro-
peptide can result in mono-transmission or co-transmission, which is solely 
determined by the enzyme involved in the cleaving process. Substance P 
preferably binds to neurokinin 1 (NK1) receptors, but it also displays affinity for NK2 
and NK3 receptors. In the activated state, peptide-receptor-complexes internalize 
into the target cell in endosomes. This internalization occurs within one minute 
after activation of the receptor by substance P. Studies in spinal cord and striatum 
indicate that after 30 minutes the cell membrane will return to its original state 
(Mantyh et al., 1995a; Mantyh et al., 1995b; Wang & Marvizon, 2002), 
1.5.3   Clinical targets of substance P 
In the early eighties, the first agonists and antagonists fort the neurokinin 
receptors became available. They were all based on peptide structures and were 
found to be adequate tools for investigation of the physiological role of substance 
P. Clinically these compounds were less relevant, because they did not pass the 
gastro-intestinal tract due to metabolic instability. 
A major breakthrough in substance P research took place in the beginning of the 
nineteen-nineties, when the first selective non-peptidergic NK1 receptor 
antagonists were synthesized (Snider et al., 1991). These new compounds made it 
possible to clinically target the substance P system, because they were 
metabolically more stable and thus suitable for oral administration. The initial 
therapeutic target for the NK1 antagonists was analgesia, because of substance P’s 
alleged role in nociception. However, the first clinical results were disappointing, 
but new therapeutic targets soon emerged. Primarily based on the anatomical 
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postrema, striatum, amygdala and PAG) emesis, depression and schizophrenia 
were among the candidate therapeutic targets. 
1.5.4   Substance P and pain 
Initially substance P research was focused on the role of substance P in pain 
transmission. In the spinal cord substance P is abundantly present. When the 
sensory nerve endings are stimulated, substance P is massively excreted in the 
dorsal horn and a pain signal is perceived. For example capsaicin (the active 
compound in Spanish peppers) induces, when injected subcutaneously, a severe 
pain sensation. This pain sensation is mediated by substance P interneurons. 
These interneurons are part of glutamatergic pain transmission cascades in the 
spinal cord. Unfortunately, blocking the effect of substance P by selective NK1 
receptor antagonists did not alleviate the pain. It appeared, that pain is perceived 
through two different pathways and substance P plays a role in only one of these 
pathways. Thus pain signals were still able to enter the brain through the second 
pathway, making substance P a less interesting target to alleviate pain. 
1.5.5   Substance P and affective disorders 
In the 80’s of the last century it became clear, that substance P might be involved 
in affective disorders. It appeared that intra cranial injection of substance P or 
particular fragments leads to anxious behavior. More extensive research was, 
however, impossible because the right pharmacological tools were not available at 
the time. This changed when a non-peptidergic and selective substance P 
antagonist became available in 1991. After the disappointing results in analgesia 
experiments, which are partly explained by the poor penetration of NK1 antagonists 
into the brain, a new therapeutic target was found in emesis (Urban & Fox, 2000). 
The ability of NK1 antagonists to suppress emeses was a major success. Aprepitant 
is a selective NK1 receptor antagonist that effectively prevents cisplatin-induced 
emeses. Its mode of action is in the brain stem solitary tract, the emeses centre, 
where it blocks substance P induced emeses. 
In 1998 Kramer and colleagues from Merck research laboratories published a paper 
in Science, wherein preclinical and clinical evidence was presented for 
antidepressant activity of NK1 antagonists (Kramer et al., 1998). Clearly, this 
stimulated preclinical research into the role of substance P in affective disorders. 
For instance, substance P and NK1 receptors were found in brain areas involved in 
emotion, stress and arousal, such as the amygdala and the limbic system (Harbuz 
& Jessop, 2001). It also appeared that chronic antidepressant treatment in rats 
reduces substance P concentrations in these brain areas (Shirayama et al., 1996). 
A confounding factor was the species variety of NK1 receptors, which has hindered 
research into the role of substance P in affective disorders considerably. Because 
the alleged antidepressant effect of NK1 antagonists could not be tested in rat and 
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mice models of depression, research had to be redirected to other species such as 
gerbils, guinea pigs and tree shrews. For instance, in the social investigation test in 
gerbils, NK1 receptor antagonists (dose-dependently) increased the time spent on 
social investigation to a similar extent as the anxiolytic drug chlordiazepoxide 
(Gentsch et al., 2002). Neonatal vocalizations after maternal separation in guinea 
pigs were reduced after treatment with antidepressants, but not with anxiolytics. It 
was discovered that the NK1 receptor antagonist L-733,060 was also able to reduce 
these vocalizations (Kramer et al., 1998), suggesting again that NK1 receptor 
antagonists may have antidepressant properties as well. Such combined anxiolytic 
and antidepressant activity would be a positive feature of NK1 receptor 
antagonists, because comorbidity of anxiety disorders and depression is high. 
1.5.6   Biological substrate for the antidepressant activity of NK1 
antagonists 
Several attempts have been made to define the biological substrate for the 
antidepressant activity of NK1 antagonists, and to give substance P a place in 
current hypothesis of major depression.  
1.5.6.1   Substance P and the monoamine hypothesis 
Co-transmission of substance P and serotonin has been shown for descending 
projections from raphe nuclei to the spinal cord. Moreover, in humans it has been 
shown that 50 % of the dorsal raphe neurons co-express serotonin and substance 
P (Sergeyev et al., 1999). However, co-localisation could not be demonstrated in 
rats. An electrophysiological study in brain slices has shown that substance P does 
not directly interact with serotonergic neurones. Excitation of serotonergic 
neurones by substance P appears to be indirectly through glutamatergic 
interneurones, and can be blocked by the glutamate AMPA receptor antagonist 
CNQX (Liu et al., 2002). Apparently, species differences do not only relate to the 
NK1 receptor subtype, but also to the anatomical organization of substance P 
neurones. This complicates research into the functionality of substance P 
considerably. Because depression research is mostly done in mice and rats, any 
extrapolation, in the case of substance P and NK1, to humans must be treated with 
caution. Yet the obtained data from research may give some indication, as 
illustrated by a study in guinea pigs, wherein an increase in firing rate of dorsal 
raphe serotonergic neurons was observed after administration of NK1 receptor 
antagonists, which had also been observed in mice (Conley et al., 2002; Santarelli 
et al., 2001). Interestingly, the firing rate was increased after blockade of the NK1 
receptor, without a subsequent increase in basal serotonin efflux in the projection 
area. A lot of functional studies have been performed in NK1 receptor knock-out 
mice. In these animals the 5-HT1A receptor appeared to be desensitized. 
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according to some groups this a crucial aspect of the antidepressant effect of 
SSRIs (Santarelli et al., 2001; Froger et al., 2001).  
Substance P interacts not only with the serotonergic system, but also with the 
noradrenergic system. Substance P containing fibers have also been identified in 
the locus coeruleus and NK1 receptors are found on the noradrenergic cell bodies 
(Hahn & Bannon, 1998). Like serotonergic neurons, the firing rate of noradrenergic 
neurons increases after application of NK1 receptor antagonists, but in contrast to 
serotonin, an increased efflux of norepinephrine was observed in the dorsal 
hippocampus and frontal cortex of the guinea pig (Millan et al., 2001; Maubach et 
al., 2002). 
1.5.6.2   Substance P and the HPA-axis hypothesis 
Chronic stress or a traumatic life event is thought to play a role in the etiology of 
major depression. Experimental acute and chronic stressors are known to alter the 
synthesis and secretion of various neuropeptides, including CRH, vasopressin, 
neurotensin and opioid peptides in various brain areas. Substance P neurons are 
equally responsive to aversive stimuli. Intermittent footschock in rats reduced 
substance P content in the ventral tegmental area, olifactory tubercle and several 
hypothalamic nuclei (Bannon et al., 1986). At the same time, an increased 
substance P concentration was observed in the medial septum and dentate gyrus 
nuclei (Siegel et al., 1987). NK1 receptor internalization has been shown in the 
basolateral amygdala after maternal separation in guinea pigs and after 
immobilization stress in gerbils (Kramer et al., 1998; Smith et al., 1999). In gerbils 
the NK1 receptor antagonist L-760,735 was able to prevent this internalization. 
Summarizing, substance P plays a role in stress- induced mechanisms in the brain, 
probably via activation of NK1 receptors. Arguably, NK1 receptor antagonists may 
be able to alleviate stress-induced symptoms of depression. 
1.5.6.3   Substance P and the neuroplasticity hypothesis 
The role of neuroplasticity in affective disorders has been discussed (see 1.1.3). 
Several studies support a role for substance P and its preferred NK1 receptor in 
brain plasticity and neurogenisis. Persistent pain results in a stress-like effect on 
neurogenisis in the dentate gyrus of rat and decreases BDNF in the hippocampus 
(Duric & McCarson, 2006). Indeed NK1 knockout mice appear to have a higher rate 
of neurogenisis in the dentate gyrus and an increased level of BDNF (Morcuende et 
al., 2003) 
1.5.6.4   Clinical support for a role of SP in depression 
Attempts to support and explain the antidepressant properties of NK1 antagonists 
have also been made in clinical settings. Infusion of substance P in healthy young 
men led to a worsening of mood, compared to placebo (Lieb et al., 2002). A post 
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mortem study could demonstrate significant differences in NK1 receptors densities 
in the anterior cingulate cortex between healthy volunteers and patients with 
unipolar depression, bipolar disorder and schizophrenia (Burnet & Harrison, 2000). 
In contrast, a post-mortem study in patients with major depression showed 
decreased binding of substance P in the rostral orbitofrontal cortex compared to 
control individuals (Stockmeier et al., 2002). Furthermore, a preliminary study in 
patients with major depression has shown significantly increased serum levels of 
substance P, when compared to healthy volunteers (Bondy et al., 2003).  
A follow up study with the NK1 antagonist MK-869 was performed, but could not 
demonstrate significant differences, when compared to placebo and the reference 
compound fluoxetine. Yet, the investigators claimed a significantly improved 
efficacy in severely depressed patients (Rupniak & Kramer, 1999). Other NK1 
receptor antagonists, such as NKP 608 of Novartis and TAK 637 of Takeda, have 
also been the subject of clinical trials. However, the development of NKP 608, 
TAK637 and MK 869 has been discontinued, because the results were not as good 
as expected. However, there may yet be a role for substance P and other 
neuropeptides in affective disorders. Major depression is a heterogeneous disease, 
and the role of neuropeptides may be too small to demonstrate significant 
differences in placebo controlled clinical studies. Clearly, more research is required 
to establish the exact role of substance P and NK1 receptors in affective disorders.  
1.6   Scope of the thesis 
Depression is a multifactorial disease, with both genetic and environmental factors 
likely to play a role in its etiology. Traditionally, research has focused on the role of 
monoamines and their receptors in both the neurobiology and pharmacotherapy of 
depression. However, given the complexity of the CNS it is conceivable that other 
neuronal systems are involved. With the discovery that neurokinine NK1 receptor 
antagonists display potential antidepressant activity, research into the substance P-
NK1 peptidergic system has intensified. This thesis investigates the effects of a NK1 
receptor antagonist relative to established antidepressants on several behavioral 
and biochemical markers in the psychosocial stress paradigm in tree-shrews. This 
animal model for depression has a high face-, predictive- and construct-validity. 
NK1 receptor antagonists have been reported to augment the increase of 
extracellular 5-HT levels caused by an SSRI in rats, which makes them potential 
candidates for antidepressant augmentation strategies. In view of reported NK1 
receptor species differences, it was investigated whether this augmentation also 
takes place in guinea pigs. Knowledge of neuropeptide function in the CNS is 
severely limited due to the problems encountered when trying to measure these 
compounds in vivo. To circumvent this problem, sampling technique and chemical 
analysis of neuropeptides were improved, allowing a more reliable measurement of 
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The aims of the research presented in this thesis are: 
• To assess behavioral, humeral, brain-
metabolic and immunological parameters 
of the NK1 receptor antagonist L-730735 
as a putative antidepressant in the 
chronic psychosocial stress paradigm in 
tree-shrews and compare them to 
classical antidepressants. 
• To study the effects of combined 
administration of a NK1 receptor 
antagonist and an SSRI on extracellular 
5-HT levels in the guinea pig brain. 
• To improve the in vivo assessment of 
neuropeptides, in particular substance P, 
in the brains of laboratory animals.  
1.6.1   Outline of the thesis 
In chapter 2, the behavioral and endocrine effects of a classical antidepressant 
and L-760735, a NK1 receptor antagonist, are compared in the tree-shrew chronic 
psychosocial stress model. 
In chapter 3 the effects of chronic psychosocial stress in tree-shrews on brain 
metabolites, neurogenesis and hippocampal volume are examined. Furthermore, 
the effects of both clomipramine and L-760735 administration on these parameters 
are investigated. 
In chapter 4 the effects of chronic psychosocial stress alone and in combination 
with various antidepressants and L-760735 on stress responses and immune 
function are studied in the tree-shrew model. 
In Chapter 5 the effects of combined administration of fluoxetine, an SSRI, and 
GR 205171, a NK1 receptor antagonist, on extracellular concentrations of 
serotonin, norepinephrine and dopamine are studied in guinea pigs. 
In chapter 6 several aspects of a microdialysis approach were improved, to 
enable a more reliable and sensitive in vivo assessment of small neuropeptides, 
including substance P, in the brains of laboratory animals. 
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In chapter 7 a new LC-MS/MS method is developed and discussed, which can be 
used to measure substance P concentrations in brain microdialysates. The new 
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